- Home
- ALDX vs AMCX Comparison
ALDX vs AMCX Comparison
Compare ALDX & AMCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALDX
- AMCX
- Stock Information
- Founded
- ALDX 2004
- AMCX 1980
- Country
- ALDX United States
- AMCX United States
- Employees
- ALDX N/A
- AMCX N/A
- Industry
- ALDX Biotechnology: Pharmaceutical Preparations
- AMCX Cable & Other Pay Television Services
- Sector
- ALDX Health Care
- AMCX Telecommunications
- Exchange
- ALDX Nasdaq
- AMCX Nasdaq
- Market Cap
- ALDX 313.4M
- AMCX 312.4M
- IPO Year
- ALDX 2014
- AMCX 2011
- Fundamental
- Price
- ALDX $5.60
- AMCX $7.82
- Analyst Decision
- ALDX Strong Buy
- AMCX Sell
- Analyst Count
- ALDX 2
- AMCX 5
- Target Price
- ALDX $9.50
- AMCX $6.50
- AVG Volume (30 Days)
- ALDX 715.8K
- AMCX 383.8K
- Earning Date
- ALDX 11-06-2025
- AMCX 11-07-2025
- Dividend Yield
- ALDX N/A
- AMCX N/A
- EPS Growth
- ALDX N/A
- AMCX N/A
- EPS
- ALDX N/A
- AMCX N/A
- Revenue
- ALDX N/A
- AMCX $2,354,176,000.00
- Revenue This Year
- ALDX N/A
- AMCX N/A
- Revenue Next Year
- ALDX $36.23
- AMCX N/A
- P/E Ratio
- ALDX N/A
- AMCX N/A
- Revenue Growth
- ALDX N/A
- AMCX N/A
- 52 Week Low
- ALDX $1.14
- AMCX $5.41
- 52 Week High
- ALDX $7.20
- AMCX $10.60
- Technical
- Relative Strength Index (RSI)
- ALDX 59.73
- AMCX 48.76
- Support Level
- ALDX $5.13
- AMCX $7.77
- Resistance Level
- ALDX $5.78
- AMCX $8.16
- Average True Range (ATR)
- ALDX 0.23
- AMCX 0.31
- MACD
- ALDX 0.06
- AMCX -0.09
- Stochastic Oscillator
- ALDX 84.00
- AMCX 7.28
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
About AMCX AMC Networks Inc.
AMC Networks owns several linear pay-TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network, reached 60 million pay-TV households in the US at the end of 2024. The firm also had nearly 12.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.